CU researchers now better understand ovarian cancer tumors and treatment outcomes

September 15, 2020

After nearly four years of work, a group of researchers and clinicians from the University of Colorado (CU) published a paper this week in the Clinical Cancer Research that shares findings from research looking at how the composition of ovarian cancer tumors changes during chemotherapy and contributes to therapeutic response.

While the standard of care consisting of surgery and chemotherapy for ovarian cancer patients is usually effective, disease recurrence and resistance are common. In fact, according to the American Cancer Society, ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. In 2020 it is estimated that 13,940 women will die from ovarian cancer. There is currently an unmet clinical need to predict patients' response to chemotherapy, which was the focus of the research team.

"Almost all patients initially respond, however, almost all patients will recur," says Benjamin Bitler, PhD, CU Cancer Center member and corresponding author. "On the other hand, there is a small percentage of patients will never recur or remain in remission beyond five years. We are working to be able to better predict a patients' response to chemotherapy."

This group of researchers and clinicians set out in November 2016 to focus on identifying potential biomarkers or pathways to better predict how a patient's tumor would respond to therapy. This information could change maintenance and surveillance and will take a step towards a precision medical approach for each patient.

"Our ultimate goal is that someone who is diagnosed with ovarian cancer would be able to come in and we would be able to take the primary tumor and use the two major technologies described in the research study, transcriptomics using Nanostring and multi-spectral immunohistochemistry (IHC), to get an idea about what is being expressed and what the tumor microenvironment looks like," says Bitler.

Multi-spectral IHC is a way of characterizing the tumor's composition. Tumors are not made of only tumor cells; they also include among other things, blood vessels, stroma and immune cells. Other research leading up to this has shown the tumor composition correlates to the patient's prognosis suggesting that the composition of the tumor likely holds clues as to therapeutic response. The major strength of multi-spectral IHC is that the location of the different cell types is kept intact, allowing for an added dimension of data, which is the physical location of each cell type.

"However, there is a limitation with multi-spectral IHC, which is that right now we can only identify nine different markers. This is a problem when you think there are likely more than 9 different subpopulations of cells within the tumor," explains Bitler. "Therefore, to improve our resolution of the tumor composition we are using transcriptomic analysis in parallel to further infer into the tumor composition."

Between these two technologies, the team can characterize the important players that might be involved in promoting the tumor progression or response to therapy. In the present study, the research group examined ovarian cancer tumors before and after chemotherapy, with the goal of describing how chemotherapy remodels the tumor composition. Building on this research study the long-term objective of the ovarian cancer research group to leverage our understanding of the effects of chemotherapy on the tumor to predict response and disease recurrence.

Looking forward in ovarian cancer care

One of the groups' major funding sources to this point was an award through the Developmental Therapeutics program, one of four CU Cancer Center research programs.

"That award let us get to where we are right now but ultimately, we want to examine primary tumors from 500 patients."

The team is getting ready to submit for a large federal grant later this year that will help with achieving our long-term goals. Dr. Aaron Clauset from CU Boulder is an expert in machine learning and network analysis. He will significantly contribute to aspects of the grant by developing machine learning approaches that predict therapeutic response.

"It is not going to happen in the next year or two but our long-term vision is that patients come in, get their tumor biopsied and within weeks we inform the clinician of the likelihood that his/her patient will be a good responder or be resistant to chemotherapy," says Bitler.

Bringing two campuses together

"Another part of this project that I think is a strength, is that we were starting to bridge the gap between the CU Anschutz and CU Boulder campus to leverage the expertise, computer modeling and machine learning that is being developed in Boulder and apply it to some of the biomedical questions we have on the Anschutz campus," says Bitler.

This study is made up of 15 researcher or clinicians, nine of which are CU Cancer Center members:This group used a multidisciplinary approach to get to this point, which demonstrates the strength of putting the expertise of the two campuses together.

"This publication is a major milestone and a step in the right direction to show that we can work together as a team to address challenges that are facing patients with ovarian cancer."
In addition to the project highlighted in this research study, The CU ovarian cancer research group also has on-going research projects. These projects include early detection of ovarian cancer (Dr. Behbakht; The Emily McClintock-Addlesperger Endowed Chair for ovarian cancer research), improving immunotherapeutic response (Drs. Richer, Slansky and Jordan), and uncovering new therapeutic targets (Drs. Sikora and Kumar).

University of Colorado Anschutz Medical Campus

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to